Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Blood (2023) 142 (20): 1697–1707.

https://doi.org/10.1182/blood.2023020630

Published: 2023

Includes: Supplemental data

Journal Articles

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, Ivory Tang, Yanis Tazi, Amanda Gilkes, Ian Thomas, Lars Bullinger, Konstanze Döhner, Hartmut Dohner, Brian Huntly, Nigel H. Russell, Sanam Loghavi, Elli Papaemmanuil

Blood (2023) 142 (Supplement 1): 818.

https://doi.org/10.1182/blood-2023-179598

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

Nigel H. Russell, Abin Thomas, Robert Hills, Ian Thomas, Amanda Gilkes, Nuria Almuina, Sarah Burns, Lucy Marsh, Georgia Andrew, Nicholas McCarthy, Jennifer Byrne, Rob Sellar, Richard J. Kelly, Paul Cahalin, Ulrik Malthe Overgaard, Priyanka Mehta, Mike Dennis, Steve Knapper, Sylvie D Freeman

Blood (2023) 142 (Supplement 1): 830.

https://doi.org/10.1182/blood-2023-185956

Published: 2023

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood (2022) 140 (22): 2407–2411.

https://doi.org/10.1182/blood.2022016567

Published: 2022

Includes: Supplemental data

Journal Articles

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Blood (2022) 140 (Supplement 1): 6293–6294.

https://doi.org/10.1182/blood-2022-159212

Published: 2022

Journal Articles

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar

Blood (2022) 140 (Supplement 1): 3377–3378.

https://doi.org/10.1182/blood-2022-159154

Published: 2022

Journal Articles

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Blood (2022) 140 (Supplement 1): 532–533.

https://doi.org/10.1182/blood-2022-162245

Published: 2022

Journal Articles

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Francis J. Mussai, Ian Thomas, Cono Ariti, Laura Upton, Mia Sydenham, Alan K. Burnett, Steve Knapper, Priyanka Mehta, Mary Frances McMullin, Mhairi Copland, Nigel H. Russell, Robert Hills

Blood (2021) 138 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2021-148323

Published: 2021

Journal Articles

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

Sun Loo, Richard Dillon, Natasha S Anstee, Ing S Tiong, Adam Ivey, Nicola Potter, Jad Othman, Manohursingh Runglall, Jelena Jovanovic, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2364.

https://doi.org/10.1182/blood-2021-149301

Published: 2021

Journal Articles

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Mhairi Copland, Cono Ariti, Ian Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahidul Islam, Lars Kjeldsen, Alan K. Burnett, Robert Hills, Nigel H. Russell, Mike Dennis

Blood (2021) 138 (Supplement 1): 1266.

https://doi.org/10.1182/blood-2021-147802

Published: 2021

Journal Articles

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Xu Wang, Ian Thomas, Cono Ariti, Mike Dennis, Priyanka Mehta, Nigel H Russel, Mia Sydenham, Robert Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Kathleen Kerr, Roland B. Walter, Megan Othus

Blood (2021) 138 (Supplement 1): 220.

https://doi.org/10.1182/blood-2021-151597

Published: 2021

Journal Articles

A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial

Charlotte A Bradbury, MD MSc, FRCP, FRCPath, PhD, Rosemary Greenwood, Julie Pell, Katie Breheny, Rebecca Kandiyali, Jenny Ingram, Ian Thomas, Catherine Bagot, MD FRCPath, MBBS, Quentin Hill, HaemSTAR Collaborators, Nichola Cooper

Blood (2020) 136 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2020-143563

Published: 2020

NARROW

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Influence of Bone Marrow Blast Enumeration and Co-Occurring Myelodysplasia Related Gene Mutations in NPM1 -Mutated Myeloid Malignancies

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

High Sensitivity Detection of FLT3 -ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only